Specialty pharmacy is the fastest-growing and highest-margin segment of pharmaceutical distribution and benefit management. Specialty drugs — complex biologics, orphan drugs, cell and gene therapies, and high-cost small molecules — account for approximately 55% of total drug spend despite representing only 2-3% of prescriptions. The distribution of cell and gene therapies, with their extreme temperature requirements, short stability windows, and patient-specific manufacturing, requires purpose-built logistics infrastructure that is creating new competitive dynamics in specialty distribution. McKesson, AmerisourceBergen, and CVS Specialty are the three dominant specialty drug distributors.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Specialty Pharmacy Market Dynamics
• Cell and Gene Therapy Distribution
• Biologics and Biosimilars
• Rare Disease Drug Management
• Specialty Distribution Competitive Landscape
• Hub Services
• Patient Support Programs
Table of Contents
1. Executive Summary
2. Market Overview
3. Specialty Pharmacy Market Dynamics
4. Cell and Gene Therapy Distribution
5. Biologics and Biosimilars
6. Rare Disease Drug Management
7. Specialty Distribution Competitive Landscape
8. Hub Services
9. Patient Support Programs
10. Competitive Landscape
11. Regional Market Analysis
12. Strategic Conclusions and Recommendations
13. Appendix
List of Tables
Table 1. Market Overview and Key Data 2025
Table 2. Competitive Landscape 2025
Table 3-8. Topic-Specific Analysis Tables
Table 3. Leading Companies — Portfolio and Strategy Assessment 2025
Table 4. M&A and Partnership Activity 2023-2025
Table 5. Regional Analysis
Table 6. Key Risks and Mitigation Strategies
Companies Profiled
AbbVie
Alexion
BioMarin
Blueprint Medicines
Sanofi Genzyme
Ultragenyx
Vertex
